Navigation Links
Stem Cell Therapy Disappoints Against Rare Kidney Ailment
Date:9/12/2007

Transplanted cells don't boost AL amyloidosis outcomes, study finds

WEDNESDAY, Sept. 12 (HealthDay News) -- In a disheartening result that confounds existing research, a team in France says a new stem cell therapy for a rare kidney disease is no better than the usual chemotherapy-only approach.

The study "has major limitations and must be interpreted with caution," said Dr. S. Vincent Rajkumar, a professor of medicine at the Mayo Clinic. Still, he said, it conflicts with "a widely held belief" that the stem-cell approach -- combined with aggressive chemotherapy -- is better for some patients.

But there's also some good news. The study doesn't reject the possibility that stem-cell transplants may be a better bet in facilities that specialize in the procedure, Rajkumar added.

The findings are published in the Sept. 13 issue of the New England Journal of Medicine.

AL amyloidosis disease is one of several caused by abnormal proteins that deposit themselves in various organs of the bodies and cause major damage, Rajkumar explained.

An estimated 1,200-3,200 people will develop the condition in the United States each year. The disease is similar to a more common condition called multiple myeloma.

Survival with AL amyloidosis is typically measured in months. The average survival time is a year without an effective treatment, said study lead author Dr. Arnaud Jaccard of the Centre Hospitalier Universitaire in Limoges, France.

But, according to Jaccard, there's plenty of controversy about which treatment is best.

In the new study, researchers followed two groups of 50 patients each. One group received treatment with high-dose chemotherapy (a drug called melphalan) followed by stem cell transplants; the other received standard-dose melphalan-plus-dexamethasone chemotherapy.

The researchers followed the patients for an average of three years to see what happened to them.

The team found no major difference in survival between the two groups.

There are some caveats, however, Rajkumar said. For one, few patients took part in the study, lowering its statistical power. For another, many of the patients who received stem-cell transplants got them at facilities that didn't have much experience in the procedure, which is very complicated, he said.

Considering that, it's possible that treatment with stem-cell treatments may be a better option in some cases, Rajkumar said.

More information

For more on AL amyloidosis, visit the Amyloidosis Support Network.



SOURCES: S. Vincent Rajkumar, M.D., professor, medicine, Mayo Clinic, Rochester, Minn.; Arnaud Jaccard, M.D., researcher, Centre Hospitalier Universitaire, Limoges, France; Sept. 13, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Acupuncture May Help Chemotherapy Side Effects
4. Antioxidants protect health tissue in people undergoing radiation therapy.
5. Distraction therapy found very effective in postoperative patients
6. Gene Therapy shows promise in treating Hemophilia
7. "Make AIDS Therapy affordable" - Physicians demand
8. Acupuncture superseeds massage therapy for short term relief of pain
9. Hormone replacement Therapy a headache
10. Simple Therapy
11. Ovarian cancer in relationship with Hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... ... , ... Usually, the impending arrival of warmer weather means the gleeful banishment ... double chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic ... double chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a ... time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service ... uses biometric face recognition to enable users to check in and out from ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder ... few medical professionals in the country to sit on the 2017 National Advisory Board ... just 2 years Dr. Harper helped propel the clinic from a small start-up to ...
(Date:3/28/2017)... ... 28, 2017 , ... The Lice Treatment Center® booth at ... was a busy spot this year. Liz Solovay and Adrian Picheny, the firm’s ... among camp communities during the upcoming 2017 camping season. “Lice infestations at some ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Summary This report provides all the information ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... Germany , March 27, 2017 ... over 7,000 attendees and more than 600 exhibitors ... and discover opportunities and solutions that will advance ... 6 April 2017 at the Messe Stuttgart, ... the preeminent medical technology platform showcasing the key ...
Breaking Medicine Technology: